FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012078408> ?p ?o ?g. }

• W2012078408 endingPage "1700" @default.
• W2012078408 startingPage "1693" @default.
• W2012078408 abstract "Cyclooxygenase-2 (COX-2) is frequently overexpressed in human malignancies and plays a crucial role in tumorigenesis and cancer progression. The present study aimed to investigate the expression and clinical significance of COX-2 and survivin (SUV) in human osteosarcomas (OS), and explore the effects and molecular mechanisms of a selective COX-2 inhibitor NS-398 and SUV on tumor proliferation and apoptosis. Fifty cases of human OS and osteochondromas (OC) were collected. The expression of COX-2 and SUV was assessed using immunohistochemical assays in biopsy samples. MG-63 human OS cells were treated with different concentrations of NS-398, used to investigate their effects on cell proliferation and apoptosis. The recombinant small hairpin RNA adenovirus vector rAd5-SUV was constructed, and the effects and molecular mechanisms of knockdown of SUV on proliferation and apoptosis were evaluated in MG-63 cells. A subcutaneous xenograft tumor model was established, validating the effects of rAd5-SUV on tumor growth in vivo. Based on the results, the expression of COX-2 and SUV in OS showed a higher strong reactivity rate compared with OC (73.3 vs. 25.0%, P=0.001; 63.3 vs. 30.0%, P=0.02), but it did not correlate with the clinicopathological characteristics of OS. NS-398 inhibited proliferation, induced apoptosis and decreased the mRNA expression of COX-2 and SUV in MG-63 cells. Furthermore, adenovirus-mediated knockdown of SUV inhibited proliferation, induced apoptosis, reduced the expression of proliferating cell nuclear antigen (PCNA), increased the expression of caspase-3 (CAS-3) and slowed the growth of xenograft tumors in MG-63 cells. Taken together, the expression of COX-2 and SUV is closely correlated with human OS, and inhibition of COX-2 or knockdown of SUV suppresses tumor proliferation and induces apoptosis, suggesting that COX-2 may be involved in OS cell proliferation and apoptosis through SUV-mediated regulation of PCNA and CAS-3 expression, and provides a potential therapeutic strategy for the treatment of cancer." @default.
• W2012078408 created "2016-06-24" @default.
• W2012078408 creator A5003759585 @default.
• W2012078408 creator A5009844753 @default.
• W2012078408 creator A5050834366 @default.
• W2012078408 creator A5065408173 @default.
• W2012078408 creator A5069842224 @default.
• W2012078408 creator A5087272086 @default.
• W2012078408 date "2012-08-24" @default.
• W2012078408 modified "2023-10-18" @default.
• W2012078408 title "The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway" @default.
• W2012078408 cites W1985263783 @default.
• W2012078408 cites W1991358615 @default.
• W2012078408 cites W1995484697 @default.
• W2012078408 cites W2002406642 @default.
• W2012078408 cites W2018766929 @default.
• W2012078408 cites W2036446689 @default.
• W2012078408 cites W2048380443 @default.
• W2012078408 cites W2054174105 @default.
• W2012078408 cites W2059042781 @default.
• W2012078408 cites W2064568564 @default.
• W2012078408 cites W2069478637 @default.
• W2012078408 cites W2074277744 @default.
• W2012078408 cites W2076836237 @default.
• W2012078408 cites W2078935333 @default.
• W2012078408 cites W2084549934 @default.
• W2012078408 cites W2086209079 @default.
• W2012078408 cites W2090492427 @default.
• W2012078408 cites W2099318069 @default.
• W2012078408 cites W2106787323 @default.
• W2012078408 cites W2109000034 @default.
• W2012078408 cites W2109815113 @default.
• W2012078408 cites W2117692326 @default.
• W2012078408 cites W2132600827 @default.
• W2012078408 cites W2148614508 @default.
• W2012078408 cites W2158916759 @default.
• W2012078408 cites W2161707028 @default.
• W2012078408 cites W4235997245 @default.
• W2012078408 cites W4246742253 @default.
• W2012078408 doi "https://doi.org/10.3892/or.2012.1992" @default.
• W2012078408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22922684" @default.
• W2012078408 hasPublicationYear "2012" @default.
• W2012078408 type Work @default.
• W2012078408 sameAs 2012078408 @default.
• W2012078408 citedByCount "21" @default.
• W2012078408 countsByYear W20120784082013 @default.
• W2012078408 countsByYear W20120784082014 @default.
• W2012078408 countsByYear W20120784082016 @default.
• W2012078408 countsByYear W20120784082017 @default.
• W2012078408 countsByYear W20120784082018 @default.
• W2012078408 countsByYear W20120784082019 @default.
• W2012078408 countsByYear W20120784082020 @default.
• W2012078408 countsByYear W20120784082021 @default.
• W2012078408 countsByYear W20120784082023 @default.
• W2012078408 crossrefType "journal-article" @default.
• W2012078408 hasAuthorship W2012078408A5003759585 @default.
• W2012078408 hasAuthorship W2012078408A5009844753 @default.
• W2012078408 hasAuthorship W2012078408A5050834366 @default.
• W2012078408 hasAuthorship W2012078408A5065408173 @default.
• W2012078408 hasAuthorship W2012078408A5069842224 @default.
• W2012078408 hasAuthorship W2012078408A5087272086 @default.
• W2012078408 hasBestOaLocation W20120784081 @default.
• W2012078408 hasConcept C121608353 @default.
• W2012078408 hasConcept C126322002 @default.
• W2012078408 hasConcept C153911025 @default.
• W2012078408 hasConcept C173396325 @default.
• W2012078408 hasConcept C185592680 @default.
• W2012078408 hasConcept C190232843 @default.
• W2012078408 hasConcept C190283241 @default.
• W2012078408 hasConcept C2775975398 @default.
• W2012078408 hasConcept C2777760704 @default.
• W2012078408 hasConcept C2781018059 @default.
• W2012078408 hasConcept C29537977 @default.
• W2012078408 hasConcept C34688535 @default.
• W2012078408 hasConcept C502942594 @default.
• W2012078408 hasConcept C54355233 @default.
• W2012078408 hasConcept C55493867 @default.
• W2012078408 hasConcept C555283112 @default.
• W2012078408 hasConcept C62112901 @default.
• W2012078408 hasConcept C71924100 @default.
• W2012078408 hasConcept C86803240 @default.
• W2012078408 hasConceptScore W2012078408C121608353 @default.
• W2012078408 hasConceptScore W2012078408C126322002 @default.
• W2012078408 hasConceptScore W2012078408C153911025 @default.
• W2012078408 hasConceptScore W2012078408C173396325 @default.
• W2012078408 hasConceptScore W2012078408C185592680 @default.
• W2012078408 hasConceptScore W2012078408C190232843 @default.
• W2012078408 hasConceptScore W2012078408C190283241 @default.
• W2012078408 hasConceptScore W2012078408C2775975398 @default.
• W2012078408 hasConceptScore W2012078408C2777760704 @default.
• W2012078408 hasConceptScore W2012078408C2781018059 @default.
• W2012078408 hasConceptScore W2012078408C29537977 @default.
• W2012078408 hasConceptScore W2012078408C34688535 @default.
• W2012078408 hasConceptScore W2012078408C502942594 @default.
• W2012078408 hasConceptScore W2012078408C54355233 @default.
• W2012078408 hasConceptScore W2012078408C55493867 @default.
• W2012078408 hasConceptScore W2012078408C555283112 @default.
• W2012078408 hasConceptScore W2012078408C62112901 @default.

• next